<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020267</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068173</org_study_id>
    <secondary_id>NCI-00-C-0182</secondary_id>
    <secondary_id>NCI-1034</secondary_id>
    <nct_id>NCT00020267</nct_id>
    <nct_alias>NCT00006074</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill
      tumor cells.

      PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating
      patients who have metastatic cancer that has not responded to previous therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity profile of MAGE-12 peptide vaccine in patients with
      refractory metastatic cancer that expresses MAGE-12 antigen.

      II. Determine whether an immunologic response, as measured by an in vitro sensitization
      assay, can be obtained after administration of this regimen in these patients.

      III. Determine a frequency of administration for this regimen based on immunologic response
      in these patients.

      IV. Determine other immunologic parameters in these patients treated with this regimen.

      V. Determine the clinical response rate in these patients treated with this regimen.

      PROTOCOL OUTLINE: This is a randomized study. Patients are stratified according to disease
      (metastatic cutaneous melanoma vs other tumor types). Patients are randomized to one of two
      treatment arms.

      Arm I: Patients receive MAGE-12 peptide vaccine emulsified in Montanide ISA-51 adjuvant
      subcutaneously (SC) weekly for 4 doses.

      Arm II: Patients receive MAGE-12 peptide vaccine emulsified in Montanide ISA-51 adjuvant SC
      once every 3 weeks for 4 doses.

      Patients with progressive disease may receive interleukin-2 IV over 15 minutes every 8 hours,
      beginning on the day after each immunization and continuing for up to 4 days. Patients
      achieving stable disease or a mixed, partial, or complete response continue on vaccine
      therapy alone for up to 24 total doses.

      Patients are followed at 3 weeks.

      PROJECTED ACCRUAL:

      A total of 26-56 patients (13-28 per treatment arm) will be accrued for this study within 1
      year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lung Cancer</condition>
  <condition>Adult Soft Tissue Sarcoma</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Bone Cancer</condition>
  <condition>Ovarian Sarcoma</condition>
  <condition>Melanoma</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Eye Cancer</condition>
  <condition>Uterine Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>interleukin-2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAGE-12 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Histologically documented metastatic cancer of one of the
        following types: Cutaneous melanoma Ocular melanoma Colorectal carcinoma Non-small cell
        lung cancer Breast carcinoma Sarcoma HLA-Cw*0702 positive MAGE-12 expression by RT-PCR
        amplified tissue analysis Failed prior standard therapy Measurable or evaluable disease No
        renal carcinoma Hormone receptor status: Not specified --Prior/Concurrent Therapy--
        Biologic therapy: At least 3 weeks since prior biologic therapy for cancer No other
        concurrent biologic therapy for cancer Chemotherapy: At least 3 weeks since prior
        chemotherapy for cancer and recovered No concurrent chemotherapy for cancer Endocrine
        therapy: At least 3 weeks since prior hormonal therapy for cancer No concurrent hormonal
        therapy for cancer No concurrent steroids Radiotherapy: At least 3 weeks since prior
        radiotherapy for cancer and recovered No concurrent radiotherapy for cancer Surgery: Prior
        surgery for cancer allowed --Patient Characteristics-- Age: 16 and over Sex: Male or female
        Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: Greater than
        3 months Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 90,000/mm3 Hepatic:
        Bilirubin no greater than 1.6 mg/dL AST/ALT less than 3 times normal Renal: Creatinine no
        greater than 2.0 mg/dL Cardiovascular: No cardiac ischemia, myocardial infarction, or
        cardiac arrhythmias (if receiving interleukin-2 (IL-2) therapy) Pulmonary: No obstructive
        or restrictive pulmonary disease (if receiving IL-2 therapy) Other: Not pregnant Negative
        pregnancy test Fertile patients must use effective contraception No active systemic
        infections No autoimmune disease, known immunodeficiency disease, or active primary or
        secondary immunodeficiency Hepatitis B surface antigen negative HIV negative No other
        active major medical illnesses (if receiving IL-2 therapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Francesco M. Marincola</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2002</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2007</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>Ewing's family of tumors</keyword>
  <keyword>adult soft tissue sarcoma</keyword>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>bone cancer</keyword>
  <keyword>breast cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>childhood cancer</keyword>
  <keyword>childhood solid tumor</keyword>
  <keyword>ciliary body and choroid melanoma, medium/large size</keyword>
  <keyword>colon cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>extraocular extension melanoma</keyword>
  <keyword>eye cancer</keyword>
  <keyword>female reproductive cancer</keyword>
  <keyword>gastrointestinal cancer</keyword>
  <keyword>genetic condition</keyword>
  <keyword>intraocular melanoma</keyword>
  <keyword>lung cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>metastatic osteosarcoma</keyword>
  <keyword>metastatic tumors of the Ewing's family</keyword>
  <keyword>muscle cancer</keyword>
  <keyword>musculoskeletal cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>osteosarcoma</keyword>
  <keyword>osteosarcoma/malignant fibrous histiocytoma of bone</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent intraocular melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>recurrent tumors of the Ewing's family</keyword>
  <keyword>recurrent uterine sarcoma</keyword>
  <keyword>skin tumor</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage IIIB, IV, recurrent, and metastatic breast cancer</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>stage IVA adult soft tissue sarcoma</keyword>
  <keyword>stage IVB adult soft tissue sarcoma</keyword>
  <keyword>stage, Ewing's family of tumors</keyword>
  <keyword>stage, adult soft tissue sarcoma</keyword>
  <keyword>stage, breast cancer</keyword>
  <keyword>stage, colon cancer</keyword>
  <keyword>stage, intraocular melanoma</keyword>
  <keyword>stage, melanoma</keyword>
  <keyword>stage, non-small cell lung cancer</keyword>
  <keyword>stage, osteosarcoma</keyword>
  <keyword>stage, rectal cancer</keyword>
  <keyword>stage, uterine sarcoma</keyword>
  <keyword>thorax/respiratory cancer</keyword>
  <keyword>uterine sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
    <mesh_term>Eye Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

